Kate Dawson from Biogen: Tecfidera Continues to Show Real World Success

It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients.

Kate Dawson, MD, from Biogen discussed some of the latest data on the medication at the annual ECTRIMS conference in London. Dawson said since its approval the research has shown that the medication has followed closely with its performance during the pre-approval trials which has in turn meant beneficial results for patients. This has included several areas including safety and time to first relapse when compared to other medications on the market.